Helicobacter pylori infection - recent developments in diagnosis

Ana Isabel Lopes, Filipa F Vale, Mónica Oleastro

Ana Isabel Lopes, Centro Académico de Medicina de Lisboa, Faculdade de Medicina da Universidade de Lisboa, 749-016 Lisboa, Portugal
Filipa F Vale, Centro de Patogénese Molecular, Unidade dos Retrovírus e Infeções Associadas, Instituto de Medicina Molecular e Instituto de Investigação do Medicamento, Faculdade de Farmácia, Universidade de Lisboa, 1749-016 Lisboa, Portugal
Mónica Oleastro, Laboratório Nacional de Referência das Infeções Gastrintestinais, Departamento de Doenças Infecciosas, Instituto Nacional de Saúde Dr Ricardo Jorge, 749-016 Lisboa, Portugal

Author contributions: Lopes AI planned the paper’s general structure, format and content; all the authors contributed equally to the paper and its final revision.

Correspondence to: Ana Isabel Lopes, Professor, MD, PhD, Centro Académico de Medicina de Lisboa, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, Código Postal 1649-035 Lisboa, Portugal. anaisalopes@sapo.pt
Telephone: +351-217-805000 Fax: +351-217-548215
Received: November 9, 2013 Revised: February 28, 2014
Accepted: April 15, 2014
Published online: July 28, 2014

Abstract

Considering the recommended indications for Helicobacter pylori (H. pylori) eradication therapy and the broad spectrum of available diagnostic methods, a reliable diagnosis is mandatory both before and after eradication therapy. Only highly accurate tests should be used in clinical practice, and the sensitivity and specificity of an adequate test should exceed 90%. The choice of tests should take into account clinical circumstances, the likelihood ratio of positive and negative tests, the cost-effectiveness of the testing strategy and the availability of the tests. This review concerns some of the most recent developments in diagnostic methods of H. pylori infection, namely the contribution of novel endoscopic evaluation methodologies for the diagnosis of H. pylori infection, such as magnifying endoscopy techniques and chromoendoscopy. In addition, the diagnostic contribution of histology and the urea breath test was explored recently in specific clinical settings and patient groups. Recent studies recommend enhancing the number of biopsy fragments for the rapid urease test. Bacterial culture from the gastric biopsy is the gold standard technique, and is recommended for antibiotic susceptibility test. Serology is used for initial screening and the stool antigen test is particularly used when the urea breath test is not available, while molecular methods have gained attention mostly for detecting antibiotic resistance.

Key words: Helicobacter pylori; Diagnosis; Endoscopy; Histology; Culture; Urea breath test; Stool antigen test; Serology; Molecular methods

Core tip: Considering the importance of a reliable diagnosis in the setting of current recommendations for Helicobacter pylori (H. pylori) eradication therapy, recent developments in both invasive and non-invasive methods may further contribute to improving H. pylori detection. The manuscript presents an extensive overview of the major advances in endoscopy, histology, culture, urea breath test, serology, stool tests and molecular methods, emphasizing their major contributions and potential shortcomings.

INTRODUCTION

A reliable primary diagnosis and control of treatment success of *Helicobacter pylori* (*H. pylori*) infection is crucial for patients with a wide spectrum of *H. pylori*-related conditions, including uncomplicated or complicated ulcer disease, mucosa associated lymphoid tissue (MALT) lymphoma, atrophic gastritis and previous partial gastric resection for gastric cancer. Accurate diagnosis of *H. pylori* infection involves the combined knowledge, effort and research of laboratories, gastroenterologists and pathologists. Traditional diagnosis is made using a combination of tests, both invasive and noninvasive. Considering the broad spectrum of diagnostic methods, only highly accurate tests should be used in clinical practice under specific circumstances and currently, the sensitivity and specificity of such tests should exceed 90%. The choice of tests usually depends on clinical circumstances, the likelihood ratio of positive and negative tests, the cost-effectiveness of the testing strategy and of the availability of the tests. The present paper aimed to present an overview of the most recent advances in both biopsy- and non-biopsy-based diagnostic methods for *H. pylori* infection (Table 1).

ENDOSCOPY

Considering that accurate prediction of *H. pylori* infection status on endoscopic images can improve early detection of gastric cancer, especially in some geographic areas, the contribution of both conventional and novel endoscopic evaluation methodologies has received increased attention, particularly in specific clinical settings. A summary of the latest endoscopic studies is presented below. Watanabe et al. studied the diagnostic yield of endoscopy for *H. pylori* infection at three endoscopist career levels - beginner, intermediate and advanced. For this study, 77 consecutive patients who underwent endoscopy were analyzed for *H. pylori* infection status by histology, serology and urea breath test (UBT). The diagnostic yield was 88.9% for *H. pylori*-uninfected, 62.1% for *H. pylori*-infected, and 55.8% for *H. pylori*-eradicated. Intra-observer agreement for *H. pylori* infection status was good (κ = 0.6) for all physicians, while inter-observer agreement was lower (κ = 0.46) for beginners than for intermediate and advanced (κ > 0.6). For all physicians, good inter-observer agreement in endoscopic findings was seen for atrophic change (κ = 0.69), but the accuracy was lower for beginners.

In 496 asymptomatic Japanese middle-aged men, a prospective evaluation (mean follow-up period of 54 years), of gastric cancer development was performed in non-atrophic stomachs with highly active inflammation identified by serum levels of pepsinogen and *H. pylori* antibody, together with a specific endoscopic feature: endoscopic rugal hyperplastic gastritis (RHG) (reflecting localized highly active inflammation). Cancer incidence was significantly higher in patients with RHG, high *H. pylori* antibody titers and low PG 1/II ratio than in patients without. Significantly, no cancer development was observed in these high-risk subjects after *H. pylori* eradication. This study emphasizes the high risk of cancer development in subjects with *H. pylori*-associated highly active non-atrophic gastritis and the utility of the two serological tests and endoscopic RHG for their identification.

Considering that *H. pylori* eradication is essential for metachronous gastric cancer prevention in patients undergoing endoscopic mucosectomy (EMR) for early gastric cancer, as reported by Fukase et al. and Lee et al. aimed to determine the optimal biopsy site for *H. pylori* detection in the atrophic remnant mucosa of 91 EMR patients. Three paired biopsies for histology were taken at the antrum, corpus lesser (CLC), and greater curve (CGC). Additional specimens were obtained at the antrum and CGC for a rapid urease test (RUT). *H. pylori* infection was defined as at least two positive specimens on histology and/or RUT. Pepsinogen levels were used to determine serological atrophy. The authors concluded that CGC is the optimal biopsy site for *H. pylori* diagnosis in EMR patients with extensive atrophy and that antral biopsy should be avoided, especially in serologically atrophic patients.

Although gastroscopic biopsy-based tests such as the RUT, histological examination, and culture have been widely used to diagnose *H. pylori* infection, many investigators have attempted to categorize the endoscopic findings characteristic of an *H. pylori*-infected stomach.

In 2002, Japanese endoscopists found that collecting venules, seen as numerous minute red dots in the gastric corpus, were a characteristic finding in the normal stomach without *H. pylori* infection, using both standard and magnifying endoscopy (identification of micromucosal patterns). This finding was termed “regular arrangement of collecting venules” (RAC). However, these findings are not a reliable method of diagnosis because of their low sensitivity and specificity.

Although magnifying endoscopy provides more precise information concerning abnormal mucosal patterns, it is not available in all endoscopy units. Moreover, its use requires training under an experienced supervisor and expertise. In addition, magnifying endoscopy is not necessarily appropriate for routine clinical practice because it is time-consuming and only a few facilities carry out this technique on a routine basis. On the other hand, endoscopic features corresponding to Sydney Sys-

### Table 1 Summary of diagnostic methods

<table>
<thead>
<tr>
<th>Method</th>
<th>Invasive/ Noninvasive</th>
<th>Reference method</th>
<th>Antibiotic resistance detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoscopy</td>
<td>Invasive</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Histology</td>
<td>Invasive</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Rapid urease test</td>
<td>Invasive</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Culture</td>
<td>Invasive</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Molecular methods</td>
<td>Both</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Serology</td>
<td>Noninvasive</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Urea breath test</td>
<td>Noninvasive</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Stool antigen test</td>
<td>Noninvasive</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

---

tem pathological findings have not yet been identified, and the diagnosis of *H. pylori* infection in the gastric mucosa by endoscopic features has not yet been established (Figure 1). In this setting, the Study Group of Japan Gastroenterological Endoscopy Society for Establishing Endoscopic Diagnosis of Chronic Gastritis performed a prospective multicenter study enrolling 275 patients, investigating the association between endoscopic findings (conventional findings and indigo carmine contrast) and histological diagnosis of *H. pylori* (antrum and corpus). It was shown that specific endoscopic findings, such as diffuse redness, spotty redness and mucosal swelling assessed by conventional endoscopy and swelling of *areae gastricae* by the indigo carmine contrast method, were useful for diagnosing *H. pylori* infection.

Cho et al.3 aimed to establish a new classification for predicting *H. pylori*-infected stomachs by non-magnifying standard endoscopy alone. A total of 617 participants who underwent gastroscope were enrolled prospectively and a careful close-up examination of the corpus at the greater curvature was performed, maintaining a distance of 10 mm between the endoscope tip and the mucosal surface. Despite being a monocenter study in which standard endoscopy was not directly compared with magnifying endoscopy, these results suggest two important contributions for prediction of *H. pylori* infection status: (1) the observation of gastric mucosal patterns using standard endoscopy and proposal of a new endoscopic classification including a normal RAC and three abnormal mucosal patterns; and (2) an accuracy of prediction of *H. pylori* positivity at least similar to that reported in magnifying endoscopy studies (sensitivity of 95.2% and specificity of 82.2%)08. In the future, multicenter trials comparing standard endoscopy against magnifying endoscopy, including changes in mucosal patterns after *H. pylori* eradication, and including endoscopists with different levels of expertise, are needed to confirm the reliability of these data.

Chromoendoscopy has also regained attention recently as an additional methodology to detect *H. pylori* in the gastric mucosa. A multicenter Japanese study involving 275 patients evaluated the possibility of diagnosing *H. pylori* by conventional endoscopy and chromoendoscopy using indigo carmine compared with histology performed according to the Sydney System7. Based on several indices, the authors obtained a sensitivity of 94% in the corpus and 88% in the antrum. However, the specificities in the corpus and in the antrum were low (62% and 52%, respectively). Another study using a Cuban adult population11 also aimed to evaluate the diagnostic yield of chromoendoscopy with red phenol at 0.1% for the detection of *H. pylori* infection against histology. This study reported a sensitivity of 72.6% (95%CI: 64.9-79.2) and a specificity of 75.5% (95%CI: 61.9-85.4). The authors concluded that it might be a useful method to diagnose *H. pylori* infection in the gastric mucosa, potentially with some specific advantages (topographic localization, avoidance of contamination and fast and immediate reading).

**HISTOLOGY**

Although histology has been considered to be the gold standard for *H. pylori* detection, the influence of clinical practice on the histopathological detection of *H. pylori* infection has been insufficiently explored. Recognizing that the number and distribution of *H. pylori* organisms vary in patients taking proton pump inhibitors (PPIs), it has been recommended to discontinue PPIs two weeks before endoscopy and to take biopsies from both the body and the antrum.

In a representative study, Lash et al.8,9 aimed to evaluate the yield of different gastric sampling strategies and to determine the adherence to the Sydney System guidelines in a nationwide sample of endoscopists in United States. Using a database of biopsy records diagnosed at a single pathology laboratory, the results of gastric biopsies taken to evaluate gastric inflammatory conditions in patients with no endoscopic lesions were reviewed. The *incisura angularis*, rarely sampled, yielded minimal additional diagnostic information and the acquisition of at least two biopsy specimens from the antrum and corpus, essentially following the Sydney System recommendations, was confirmed as a sensible strategy that guarantees the maximum diagnostic yield for the most common gastric inflammatory conditions.

---

**Figure 1 Endoscopic features of Helicobacter pylori infection (antral nodularity).**
In a Canadian study\[3\], electronic patient records were evaluated for the sites of gastric sampling and PPI use at endoscopy, collecting 150 cases with biopsies taken from both the antrum and body, which were randomly selected for pathological re-review with special stains. The gastric regions sampled, *H. pylori* distribution and influence of clinical factors on pathological interpretation were assessed. This study confirmed that, despite national and international guidelines for managing *H. pylori* infection, these guidelines are infrequently adhered to, with PPIs frequently contributing to false diagnosis, and sampling only one region increases the likelihood of missing active infection by at least 15%.

Considering that atrophy of the stomach mucosa develops in about 50% of *H. pylori* infected individuals by the age of 65, and is considered a pre-malignant lesion for gastric cancer\[14-16\], *H. pylori* eradication is recommended in the presence of atrophy\[17\], because atrophy may reverse after successful eradication therapy. It is critically important and challenging, therefore, to determine the presence or absence of *H. pylori* in patients with atrophic gastritis. During atrophy progression, however, the density of *H. pylori* in the stomach mucosa decreases, and may disappear completely during the late stages of atrophy\[14,16\]. This may explain the markedly lower sensitivity of biopsy-based tests (RUT, histology, culture) in the presence of atrophy. Similarly, UBT and antigen stool detection can also give false-negative results in these circumstances. In contrast, serology is not influenced to such an extent by a lower density of the microorganism, and is reliable even in advanced gastric body atrophy\[18\]. Maastricht guidelines updates have reserved serology for special situations, including extensive atrophy of the stomach mucosa on the basis that other tests might be misleading at a low bacterial density. Thus, the debate continues regarding the most appropriate *H. pylori* diagnostic method in atrophic gastritis.

Lan et al\[19\] aimed to evaluate the site and sensitivity of biopsy-based tests in terms of degree of gastritis with atrophy. Biopsy-based tests (i.e., culture, histology Giemsa stain and RUT) and non-invasive tests (anti-*H. pylori* IgG) were performed in 164 uninvestigated dyspepsia patients. The sensitivity of biopsy-based tests decreased when the degree of gastritis with atrophy increased, regardless of biopsy site. In moderate to severe antrum or body gastritis with atrophy, additional corpus biopsy increased the sensitivity to 16.67%, as compared with single antrum biopsy. These results confirm that in moderate to severe gastritis with atrophy, biopsy-based test should include the corpus for avoiding false negative results in *H. pylori* detection.

Since the discovery of *H. pylori*, pathologists have used different diagnostic techniques, including immunohistochemical (IHC) methods and special stains, such as Giemsa and Warthin-Starry, on an institution- and laboratory-dependent basis (with variable sensitivities and specificities for identifying *H. pylori*). On the other hand, it is clear that IHC staining is highly sensitive and specific for *H. pylori*, with the lowest rate of inter observer variation and is much faster than conventional histology\[19\]. However, the necessity for routine special stains and/or IHC stains has been debated in recent years. A recent study by Wang et al\[20\] confirmed what many pathologists assume: routine special stains, specifically IHC stains, are not cost-effective or necessary. Recently, Smith et al\[21\] in a retrospective study involving 200 consecutive gastric biopsy specimens, further confirmed that *H. pylori* is easily observed in the majority of cases with HE (sensitivity 91% and specificity 100%), remaining the most expedient and least expensive test for identifying *H. pylori* in gastric biopsies.

An institutional quality assurance study of a conventional method for the diagnosis of *H. pylori* - associated gastritis was performed by Hartman et al\[25\] in the United States, based on head-to-head evaluation by four methods, HE stain, Giemsa stain, Warthin-Starry stain, and *H. pylori* immunostaining of 356 gastric biopsy specimens. About 83% of *H. pylori* gastritis identified were diagnosed on the initial HE-stained slides, further supporting the use of routine ancillary stains to diagnose *H. pylori* infection in gastric biopsy specimens. Usually, the use of special stains is only recommended for biopsy specimens with moderate to severe chronic active or inactive gastritis in which *H. pylori* is not identified by HE staining, for post-treatment biopsy specimens and in cases in which structures “suspicious”, but not definitive, for *H. pylori* are observed by HE staining\[24\].

Both routine conventional histology-based methods and novel methods for *H. pylori* detection have increasingly focused on specific clinical settings and patient groups (bleeding peptic ulcer, gastric cancer). False-negative results may occur when using histological and RUT to detect *H. pylori* in biopsy specimens obtained during peptic ulcer bleeding episodes (PUB). Choi et al\[20\] evaluated different diagnostic methods in the specific setting of peptic ulcer, concluding that histology was the most accurate test, regardless of bleeding, compared with culture, serology and RUT. Ramirez-Lazarro et al\[28\] found that IHC and real-time PCR methods might improve the sensitivity of biopsy-based diagnosis in this specific setting (PUB).

In patients submitted to a subtotal gastrectomy due to gastric cancer, the identification and treatment of *H. pylori* are the key points in the prevention of cancer recurrence. Xu et al\[29\] evaluated the predictive value of neutrophil infiltration, a hallmark of active inflammation (updated Sydney system), as a histological marker of *H. pylori* infection, in 315 dyspeptic patients undergoing upper gastrointestinal endoscopy, including patients with a subtotal gastrectomy. The diagnosis of *H. pylori* infection was based on UBT and on anti-*H. pylori* immunoglobulin G (IgG) antibody in patient with a subtotal gastrectomy. Although neutrophil infiltration of gastric mucosa was strongly associated with overall *H. pylori* infection, in patients with a subtotal gastrectomy, the diagnostic accuracy of neutrophil infiltration in *H. pylori* infection was low.
De Martel et al.\textsuperscript{37}, using data from a large Venezuelan cohort of 1948 adults, compared the gastric detection of 
\textit{H. pylori} by polymerase chain reaction (PCR) of the \textit{vacA} gene in one antral biopsy, to the detection of \textit{H. pylori} by histopathology (HE and Giemsa staining) in five biopsies (antrum and corpus). Overall, \textit{H. pylori} was detected in 85% and 95% of the subjects by PCR and histopathology, respectively, thus confirming that histopathology on five biopsies is an accurate tool for \textit{H. pylori} detection in most subjects, compared with the PCR method on one biopsy. However, in subjects with the most severe precancerous lesions (intestinal metaplasia type \textit{III} and dysplasia), PCR displayed elevated sensitivity for detecting the bacteria (significantly more often than histopathology on a single biopsy), thus suggesting its potential usefulness in this setting.

Tian et al.\textsuperscript{36} reported a meta-analysis evaluating \textit{H. pylori} diagnostic methods in patients with a partial gastrectomy. The pooled sensitivity and specificity were 93 and 85% for histology, 77 and 89% for UBT, and 79 and 94% for RUT, respectively, thus leading to the conclusion that histology was the most reliable test in this setting. See et al.\textsuperscript{54} evaluated 91 patients requiring endoscopic mucosal resection for early gastric cancer (GC), comparing three pairs of biopsies from the antrum, CLC and CGC. The sensitivity of histology in detecting \textit{H. pylori} was significantly higher in the CGC than that in the antrum or CLC, suggesting that the CGC might be the optimal biopsy site for \textit{H. pylori} in patients with extensive atrophy.

The utility of routine biopsy of the gastric ulcer margin (currently performed to exclude malignancy) in diagnosing \textit{H. pylori} infection, has recently been re-assessed by Lin et al.\textsuperscript{39}, by examining prospectively a cohort of 50 patients with gastric ulcer (54% uninfected). Histology, RUT and UBT were compared; six biopsied specimens from the margin of the gastric ulcer and one specimen each from the antrum and body of non-ulcerous parts were obtained for histology using HE staining. The diagnostic accuracy of the histological examination of the ulcer margin was quite good and importantly, the addition of one specimen from the antrum or body did not increase its diagnostic yield, thus emphasizing its accuracy and usefulness for diagnosing \textit{H. pylori} infection in these patients.

An increasing body of evidence supports \textit{H. pylori} colonization in the esophageal mucosa of dyspeptic patients. Contreras et al.\textsuperscript{38} have further contributed to the field, with a study examining the presence of \textit{H. pylori} in the gastroesophageal mucosa by histology, fluorescence in situ hybridization (FISH) and PCR analysis of DNA (using genus- and species-specific PCR primers) extracted from gastric and esophageal biopsies of 82 symptomatic Venezuelan patients. \textit{H. pylori} in the stomach was detected by PCR and FISH, respectively, in 61% and 90% of dyspeptic patients, and in the esophagus in 70% and 73%. By combining the results of both methods, \textit{H. pylori} was observed in the gastroesophageal mucosa in 86% of patients. These findings deserve specific attention and further elucidation.

Finally, the histology reporting of gastritis of the staging system OLGA (Operative Link on Gastritis Assessment) has also been re-examined, considering its relevance to the prediction of the gastric cancer risk.\textsuperscript{39,42} Carrasco et al.\textsuperscript{43} reviewed the histology of the normal gastric mucosa, overviewing the role of \textit{H. pylori} in the multistep cascade of GC. The role of the OLGA staging system in assessing the risk of GC was emphasized; specifically, the epigenetic bases of chronic gastritis, mainly DNA methylation of the promoter region of E-cadherin in \textit{H. pylori} - induced chronic gastritis and its reversion after \textit{H. pylori} eradication. In addition, the authors discussed the finding of circulating cell-free DNA, offering the opportunity for non-invasive risk assessment of GC.

**RAPID UREASE TEST**

The RUT is based on the production of large amounts of urease enzyme by \textit{H. pylori}, which splits the urea test reagent to form ammonia, enabling its detection by a rapid indirect test. Many commercial RUTs are available, including gel-based tests, paper-based tests and liquid-based tests, providing a result in 1-24 h, depending on the format of the test and the bacterial density in the biopsy specimen. Typically, commercial RUTs have specificities above 95%-100%; however, the sensitivity is slightly less, ranging from 85%-95%\textsuperscript{34}.

Compared with histology and culture, urease tests are faster, cheaper and have comparable sensitivity and specificity in normal clinical settings. The sensitivity can, however, decrease in patients with bleeding peptic ulcers (67%-85%), as well as in patients with partial gastrectomy (79%)\textsuperscript{24,28,35}. Formalin contamination of forceps used to collect the biopsy may also contribute to reduced sensitivity\textsuperscript{34,38}.

An important conclusion of several studies is that enhancing the number of biopsy fragments and/or collecting them from various regions of the stomach (antrum and body, from example), achieves a higher sensitivity of the RUT\textsuperscript{37}. Moreover, it was shown recently that combining tissues prior to RUT increased the detection of \textit{H. pylori}, compared with testing separate specimens, and produced faster results\textsuperscript{38}.

**CULTURE**

Since the discovery of \textit{H. pylori}, bacterial culture has been used as routine diagnostic test, being considered the gold standard. Currently, the Maastricht-4 Consensus Report recommends \textit{H. pylori} culture for performing antibiotic susceptibility testing if primary resistance to clarithromycin is higher than 20% or after failure of second-line treatment\textsuperscript{79}.

Despite its long use, culture tests remain a challenge because of the fastidious nature of the bacterium, with particular growth requirements of medium and atmosphere. The most commonly used media include Bru-
cella, Columbia Wilkins-Chalgren, brain-heart infusion or trypticase agar bases, supplemented with sheep or horse blood. An alternative to blood is supplementation of the agar base with β-cyclodextrin or yolk emulsion.

The most recent advances on H. pylori culture concern growth medium composition, besides the usual serum or blood additives. A recent study showed that supplementation of media with cholesterol instead of serum was a viable option for H. pylori growth. Another original approach used liquid culture medium for the rapid cultivation and subsequent antibiotics susceptibility testing of H. pylori directly from biopsy specimens, with a final detection step by an enzyme linked immunosorbent assay (ELISA).

Concerning the growth atmosphere, H. pylori is a capnophilic organism that requires an atmosphere enriched with CO2 (varying from 5%-10%). In addition, it has been considered a microaerophile, but there is no general consensus about its specific O2 requirements. A recent advance on this topic was made by Park et al, who showed that unlike previous reports, H. pylori may be a capnophilic aerobic whose growth is promoted by atmospheric oxygen levels in the presence of 10% CO2.

Typically, culture of H. pylori is performed on gastric biopsy samples, and because bacteria display an irregular distribution in the gastric mucosa, culture of more than one biopsy, from the antrum and corpus, is sometimes mandatory, especially after antibiotic treatment. Another important issue to bear in mind is factors that may affect the outcome of H. pylori culture from endoscopic gastric mucosal specimens. Besides the issue concerning bleeding peptic ulcers, for which culture has a lower sensitivity than in nonbleeding cases, other host-related factors, such as high activity of gastritis, low bacterial load, drinking alcohol and the use of histamine H2 receptor blockers, have been recently described as the cause of failed H. pylori culture from gastric mucosa in the infected subjects.

Culturing from stools has been shown to be extremely difficult because of the complex nature of the sample regarding microbiota composition and shedding of unviable H. pylori cells, and this technique has been successful in the setting of rapid gastrointestinal tract transit. In a recent study, the authors were able to culture H. pylori in nine and 12 rectal and ileal fluids, respectively, after polyethylene glycol (colyte) ingestion in 20 healthy adults with positive UBT. Other studies have looked for the role of the oral cavity as a reservoir of H. pylori. A recent work evaluated the occurrence of the organism in subgingival plaque and was able, by culture, to recover H. pylori in nine of 30 studied patients that were H. pylori positive with RUT and histopathological examination. Thus, they concluded that detection of H. pylori in dental plaque of dyspeptic patients cannot be neglected and might represent a risk factor for recolonization of the stomach after systemic eradication therapy. The same conclusion was reached by another study in which H. pylori was detected in subgingival dental plaque of children and their families, possibly acting as a “reservoir” contributing to the intrafamilial spread.

**MOLECULAR METHODS**

Diagnostics tests rely more and more on molecular tests, which can provide faster, more accurate and sensitive detection of the bacterium than conventional methods, with the possibility of extension to other purposes, such as detection of antibiotic resistance and virulence determinants, and bacterial quantification. Moreover, biological samples other than gastric biopsies can be used, obtained using less invasive methods, such as stool or oral cavity samples. Whatever the case, amplification of the nucleic acids by PCR is almost always present, either conventional PCR or, increasingly, by real-time PCR.

H. pylori, like a few other bacteria, acquires resistance by mutation, which has enabled the development of numerous assays, in several formats, to detect mutations leading to resistance, especially to macrolides and fluoroquinolones. To detect H. pylori and resistances to fluoroquinolones and clarithromycin, there is a multiplex PCR followed by a hybridization and alkaline phosphatase reaction on a membrane strip (the Genotype® HelicoDR kit), that uses as a starting material biopsy specimens, as well as culture material extracted from it. The test shows a high sensitivity and permits detecting infection with multiple strains. The performance in detecting fluoroquinolone-resistance strains was, however, lower than culture, emphasizing the need to expand the range of gyrA mutations included in the kit. Several real-time PCR based assays, using either TaqMan or FRET (Fluorescence Resonance Energy Transfer) are available, as in-house assays or commercial kits, for clarithromycin resistance, performed on cultured strains, directly on biopsies or in stool samples. The latter is particularly useful as a non-invasive test in pediatric populations, where a high prevalence of clarithromycin-resistant strains is suspected, as well as for tracking the emergence of clarithromycin resistance following eradication treatment.

Recently, a dual-priming oligonucleotide (DPO)-based multiplex PCR was developed to detect both H. pylori infection and the most common point mutations conferring resistance to clarithromycin, directly on gastric biopsy specimens. This assay proved to be fast and does not require expensive instrumentation, making it valuable in countries with a high prevalence of clarithromycin resistance.

The detection of clarithromycin-resistance from formalin-fixed, paraffin-embedded gastric biopsies has also been described, and is useful mostly before treatment when culture and susceptibility testing is not available, or to detect primary resistance to clarithromycin in the case of failure of an empirical therapy based on this antibiotic. Real-time PCR assays, as well as a peptide nucleic acid-fluorescence in situ hybridization (PNA-FISH) method, have been described recently.

Another area of particular interest is the detection...
of virulence determinants, such as the cagA (cytotoxin-associated gene A) and the vacA (vacuolating cytotoxin) major toxins. Several studies showed that the risk of progression of gastric preneoplastic lesions is higher in patients infected with strains harboring the most virulent cagA and vacA genotypes than in patients infected with the least virulent strains. Therefore, H. pylori genotyping may be useful to identify patients at high risk of progression of gastric preneoplastic lesions and who need more intensive surveillance. Concerning vacA, a novel method for genotyping the vacA intermediate gene region was reported recently, using a novel primer combination allowing the amplification of smaller DNA fragments than the original PCR, which can therefore be applied to paraffin-embedded biopsies. Patients infected with vacA I strains showed an increased risk of gastric atrophy and gastric carcinoma, with odds ratios of 8.0 (95% CI: 2.3-27) and of 22 (95% CI: 7.9-63).

CagA undergoes phosphorylation on tyrosines within the Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs at the polymorphic C-terminus. Several studies suggest a role for the polymorphic CagA EPIYA-containing region in the pathogenicity of H. pylori, although conflicting results have been reported. The in vivo role of this region was emphasized recently in a study showing that infection with strains harboring two or more CagA EPIYA C motifs was associated with the presence of surface epithelial damage, and with atrophic gastritis and gastric carcinoma. Moreover, the presence of two or more CagA EPIYA C motifs increased the risk of atrophic gastritis from 7.3 (95% CI: 2.1-25) to 12 (95% CI: 2.5-58) and of gastric carcinoma from 17 (95% CI: 5.4-55) to 51 (95% CI: 13-198), when compared with one EPIYA C motif. Therefore, genotyping H. pylori virulence determinants could represent a useful approach in defining severe gastric-disease risk.

Bacterial quantification can also be important for clinical management of the infection; for example, for monitoring the treatment outcome or in particular settings, such as upper gastrointestinal bleeding.

A recently developed real-time quantitative PCR assay based on H. pylori ureC (single copy gene) copy number proved to be around 10 times more sensitive than the conventional PCR method. Moreover, the copy number of ureC was significantly increased when overall gastritis, bacterial density, chronic inflammation and intestinal metaplasia were present. Nevertheless, further studies are necessary to determine the optimum cut-off point, making it possible to differentiate between asymptomatic colonization and infection with clinical implications for patients. These highly sensitive real-time quantitative PCRs can have a large application on the study of environmental reservoirs as well.

By improving our knowledge of bacteria, at the molecular level, new strategies for treatment/prevention of bacterial-associated diseases, as well as diagnostic tests, can be developed. Proteomic approaches aimed at identifying gene products differentially expressed in association with a given pathology can provide an important input towards understanding the pathways that are associated with the respective disease, contributing to the identification of novel therapeutic or diagnostic targets.

Our current knowledge on the proteome of this organism is largely based on data obtained for the soluble proteome, membrane proteome and secreted proteome of strain 26695, the first isolate to be sequenced. More recently, relevant contributions have been made through this approach, such as novel biomarkers for gastric cancer and for peptic ulcer disease.

NONINVASIVE TESTS

Although the reliability of both the 13C-UBT and a monoclonal ELISA stool test (HpSA) to diagnose H. pylori infection in very young children has been confirmed, additional background information is warranted for epidemiological studies in infants and toddlers.

UREA BREATH TESTS

The 13 C-urea breath test (13C-UBT) is one of the most reliable tests for diagnosing H. pylori infection. It is a non-invasive, simple and safe test that provides excellent accuracy both for the initial diagnosis of H. pylori infection and for the confirmation of its eradication after treatment. The simplicity, good tolerance and economy of the citric acid test meal probably make its systematic use advisable. The UBT protocol may be performed with relatively low doses (<100 mg) of urea: 75 mg or even 50 mg seem to be sufficient. With the most widely used protocol (with citric acid and 75 mg of urea), excellent accuracy is obtained when breath samples are collected as early as 10-15 min after urea ingestion. A unique and generally proposed cut-off level is not possible, because it has to be adapted to different factors, such as the test meal, the dose and type of urea, or the pre-/post-treatment setting. As positive and negative UBT results tend to cluster outside of the range between 2 and 5, a change in cut-off value within this range would be expected to have little effect on the clinical accuracy of the test. UBT is now marketed for use with a nondispersive, isotope-selective infrared spectroscope (NDIRS) or laser-assisted ratio analysis (LARA), which are reliable and valid alternatives to isotope ratio mass spectrometry (IRMS) of potential interest for epidemiologic studies of children, for screening symptomatic children before endoscopy or assessment of treatment efficacy. These devices are far smaller and cheaper, and they allow for in-office, near-immediate reading of results. Validation studies to establish the cut-off value for this test were preliminarily performed in Japan; however, further data are needed.

The 13C-UBT in adults has a high sensitivity (88%-95%) and specificity (95%-100%). However, the test has shown heterogeneous accuracy in the pediatric population, especially in young children, with values of sensitivity and specificity ranging from 75% to 100%, be-
fore and after treatment (using several protocols), despite being a simple and safe non-invasive test in children older than 6 years old\[84\]. Although several modifications have been proposed since the original description by Graham of the \(^{13}\)C-UBT to diagnose \textit{H. pylori} infection\[85\], in children, performance criteria are not yet sufficiently established\[86\]. In the specific age group of younger children, accurate non-invasive tests for diagnosing \textit{H. pylori} infection are required, as they may avoid invasive and painful procedures, such as endoscopy and blood sampling, and to overcoming the false negative results observed with gold standard tests (histology, culture, and RUT), where colonization of the stomach may be weak and patchy.

Potential explanations for UBT performance variability in children might include: (1) urease activity from the oral bacterial flora\[87\]; (2) differences in delta time (decrease in specificity if samples obtained at 15 min instead of 30 min); and (3) variability in cut-off values. The administration of \(^{13}\)C-urea in capsules to avoid activity of oral bacteria, though effective in adults, is not feasible in infants or toddlers\[88\]. Finally, the cut-off value (usually determined by a ROC curve) represents a crucial factor for the accuracy of the test, where low cut-off values might increase sensitivity but reduce specificity, and vice versa\[89\]. Additionally, the individual’s CO\(_2\) production is influenced by anthropometric characteristics, as well as by age and sex (lower in young children with relatively low weight and height)\[90\].

Leal et al\[91\] performed an informative systematic review and meta-analysis (31 articles and 135 studies from January 1998 to May 2009), aiming to evaluate the performance of the \(^{13}\)C-UBT diagnostic test for \textit{H. pylori} infection in children. Studies with at least 30 children and reporting the comparison of \(^{13}\)C-UBT against a gold standard for \textit{H. pylori} diagnosis (\textit{H. pylori} culture, histologic examination, or RUT) were included for analysis. Children were stratified in subgroups of < 6 and ≥ 6 years of age. The \(^{13}\)C-UBT performance meta-analyses showed: (1) good accuracy in all ages combined [sensitivity 95.9%, specificity 95.7%, diagnostic odds ratio (DOR) 424.9]; (2) high accuracy in children > 6 years (sensitivity 96.6%, specificity 97.7%, DOR 1042.7); and (3) greater variability in accuracy estimates and a lower specificity of the continuous UBT (BreathID) in 76 post gas patients, (gold standard). Although UBT carried out immediately after hospital discharge in a subset of 53 patients (gold standard). UBT was negative in 526 patients, but: (1) 45% patients were tested < 4 wk before the end of treatment; and (2) 23% of negative results occurred in patients recently treated. The authors emphasized the need for strict protocol adherence in clinical practice for a fully reliable UBT assessment. Velayos et al\[92\] investigated the accuracy of UBT performed immediately after emergency endoscopy in 74 patients with peptic ulcer bleeding by comparing the results with those of UBT performed after hospital discharge in a subset of 53 patients (gold standard). Although UBT carried out immediately after emergency endoscopy in peptic ulcer bleeding is an effective, safe and easy-to-perform procedure, the relatively low sensitivity and specificity suggested the requirement of a subsequent control, in accordance with recommendations concerning peptic ulcer bleeding\[93\].

Pacheco et al\[94\] evaluated the diagnostic accuracy of detecting \textit{H. pylori} infection of low dose \(^{13}\)C-UBT with early sampling at pediatric age (129 patients between the ages of 2.1 and 19 years old, median = 11.6 years) submitted to upper gastrointestinal endoscopy. The \(^{13}\)C-UBT was performed after a 4-hour fasting period with four points of collection: baseline (T0, at 10, 20 and 30 min) after ingestion of 25 mg \(^{13}\)C-urea diluted in 100 mL of apple juice; analysis of exhaled breath samples was performed with an isotope-selective infrared spectrometer. The sensitivity and specificity were similar at T10, T20 and T30 (94.7%/96.8%; 96.2%/96.1% and 96.2%/94.7%, respectively).

Recently, Queiroz et al\[95\] investigated the agreement between the \(^{13}\)C-UBT and a monoclonal ELISA (HpSA) to detect \textit{H. pylori} antigen in stool in a prospective study enrolling 414 South-American infants (123 from Brazil and 291 from Peru) aged 6-30 mo. Breath and stool samples were obtained at intervals of at least three-months. \(^{13}\)C-UBT and stool test results concurred with each other in 94.86% cases (kappa coefficient = 0.90, 95%CI: 87-92). In the \textit{H. pylori}-positive group, DOB and OD values were positively correlated (r = 0.62, P < 0.001, suggesting that both \(^{13}\)C-UBT and stool monoclonal test are reliable to diagnose \textit{H. pylori} infection in very young children.

In contrast to pediatric studies, where attention has been focused on methodological issues, in adult studies, the validity and usefulness of UBT have increasingly been evaluated in a wide spectrum of specific clinic settings. Olafsson et al\[96\] evaluated 620 UBT in 595 subjects at a gastroenterology clinic. UBT was negative in 526 patients, but: (1) 45% patients were tested < 4 wk before the end of treatment; and (2) 23% of negative results occurred in patients recently treated. The authors emphasized the need for strict protocol adherence in clinical practice for a fully reliable UBT assessment. Velayos et al\[92\] investigated the accuracy of UBT performed immediately after emergency endoscopy in 74 patients with peptic ulcer bleeding by comparing the results with those of UBT performed after hospital discharge in a subset of 53 patients (gold standard). Although UBT carried out immediately after emergency endoscopy in peptic ulcer bleeding is an effective, safe and easy-to-perform procedure, the relatively low sensitivity and specificity suggested the requirement of a subsequent control, in accordance with recommendations concerning peptic ulcer bleeding\[93\].

Few studies using UBT have been performed in patients subjected to a partial gastrectomy, a specific group in which the identification of \textit{H. pylori} infection is mostly relevant. Wardi et al\[97\] evaluated the sensitivity and specificity of the continuous UBT (BreathID) in 76 post gastrectomized patients (older than 18 years) (lowering the gastric pH by the addition of citric acid), against RUT and histology as gold standards. \textit{H. pylori} was positive in 14/76 (18.4%) patients when histology was considered as the gold standard method. The positive predictive values of the continuous UBT and the RUT were 0.64 and 0.35, respectively. The negative predictive value was high by
both the methods, 0.92 and 0.95, respectively, supporting the view that BreathID might have some reliability to exclude *H. pylori* after partial gastrectomy.

**STOOL ANTIGEN TESTS**

The stool antigen test is a non-invasive method to detect *H. pylori*, usually recommended when the UBT is not available [98]. Besides being non-invasive, the advantages of using this method include the unneeded requirement of expensive equipment and medical personnel, and the collection of the sample at home without a visit to the hospital. This method is especially relevant for children’s access to a safe diagnosis and also for its low cost [99,100].

A meta-analysis revealed that the global sensitivity and specificity of stool antigen tests are 94% (95%CI: 93-95) and 97% (95%CI: 96-98), respectively [101]. A prospective study to evaluate the efficacy of a new EZ-STEP *H. pylori* polycyclon enzyme immunoassay (EIA) stool antigen test enrolled 555 patients undergoing routine checkups. At the optimal cut-off value (optical density 0.160), this test presented high level of sensitivity (93.1%), specificity (94.6%) and accuracy (93.8%) [99].

There are two types of stool antigen tests used for *H. pylori* detection, the EIA and an assay based on immuno-chromatography. Two new stool tests were developed recently [102]. These tests are the Testmate pylori antigen EIA, in which plastic 96-well EIA microtiter plates are coated with monoclonal antibody (Mab) 21G2 [103], and the Testmate rapid pylori antigen, which is based in immuno-chromatography and is presented as a test strip. For the EIA test, a drop of the suspended stool sample or a sample of the diluted bacterial antigen sample is mixed with the peroxidase-conjugated MAb 21G2. After proper incubation and washing, the optical density is measured and considered positive if greater than 0.100. For the test strip, a drop of stool sample is applied in the specimen application of the test strip. When *H. pylori* antigens are present, they form immune complexes with the red latex-labeled MAb 21Ge and migrate by capillarity action until captured by the solid phase anti-mouse rabbit polyclonal antibodies and form a visible red test line. A control line is also present. After application of these tests to 111 stool samples, both new tests provide 100% specificity, sensitivity and accuracy [102], which is very promising. However, not all studies report these high values for sensitivity and specificity. For example, the report of Chehter et al. [104] analyzed the stools of 75 patients and determined a lower sensitivity (87.2%) and specificity (44%); Irani-khay et al. [105] analyzed the stools of 103 children and obtained similar values for sensitivity (85%), but improved specificity (85%).

Recently, five different stool antigen tests were compared: the Premier Platinum HpSA Plus test (based on monoclonal EIA; Meridian Bioscience, Inc, Cincinnati, OH, United States); the Hp Ag test (based on monoclonal EIA; Dia.Pro Diagnostic Bioprobes Srl, Milano, Italy); the ImmunoCard STAT! HpSA test (based on monoclonal lateral flow chromatography (LFC); Meridian Bioscience, Europe Srl Milano, Italy); the *H. pylori* fecal antigen test (based on monoclonal LFC; Vegal Farmaceutica, Madrid, Spain) and the one-step *H. pylori* antigen (based on LFC with polyclonal antibodies; IHP-602, ACON Laboratories, Inc, San Diego, United States). Data comparison showed an uneven performance, favoring the Premier Platinum HpSA Plus test (sensitivity 92.2%; specificity 94.4%). The selection of the stool antigen assay is very important to achieve accurate results.

Stool antigen tests are also useful to detect *H. pylori* in infected animal models, such as C57BL/6 mice [106].

**ANTIBODY - BASED TESTS**

Serology was one of the first methods used for diagnosis of *H. pylori* infection [107]. Currently, serology is recommended for initial screening, requiring further confirmation by histology and/or culture before treatment [108]. Detection of antibodies is useful for detecting past or present exposure. In fact, a limitation of serology tests is the failure to distinguish between past and current *H. pylori* infection [99]. Moreover, the antibody levels to *H. pylori* are significantly heritable. Thus, individual genetic differences of the human host contribute substantially to antibody levels to *H. pylori* [109].

Serological tests have several advantages, namely they are non-invasive and they do not produce false negative results in patients receiving treatment (proton pump inhibitors and antibiotics) or presenting acute bleeding [100].

Blood samples are used for serology testing, detecting anti-*H. pylori* antibodies (IgG) by ELISA. Recently, the performance of 29 different serological tests kits was compared, revealing sensitivities ranging from 55.6% to 100%, specificities ranging from 59.6% to 97.9 %, positive predictive values ranging from 69.8% and 100%, and negative predictive values ranging from 68.3% and 100% [106]. According to the goal, such as screening, initial diagnosis and confirmation of another test, the most appropriate kit should be chosen. Antibody-based tests for the detection of *H. pylori* are easily available, but present high negative predictive value [109]. The heterogeneity of *H. pylori* strains has been well documented, with considerable variation in the prevalence of specific strains, especially from different geographical areas [111-113], thus, the success of a serology test depends on the use of antigens that are present in *H. pylori* strains from a given population. Moreover, kits developed using *H. pylori* strains from the west are not suitable for detecting *H. pylori* infection in the East [114]. The use of high-molecular-weight cell-associated antigens that are conserved in *H. pylori* strains overcomes this limitation [115]. Several *H. pylori* immunogenic proteins have been presented as candidates to detect infection, such as the FlidD protein [116]; multiple recombinant (CagA, VacA, GroEL, gGT, HepC and UreA) proteins [118], CagA [119] or Omp18 [120].

Modifications to serology tests have been suggested, such as the automated immunoaffinity assay for *H. pylori*.
IgG detection using purified antigen of *H. pylori* immobilized on magnetic nanobeads, which is faster than ELISA and requires a smaller volume of serum\[10\]. The lateral flow immunoassay, an immunochromatographic assay, maintains the serological approach with the advantage of being fast, economic and requiring no additional equipment or experience\[19\].

Detection of gastrin and the serum PG I / II ratio combined with *H. pylori* serology is useful to predict gastric preneoplastic conditions \[11\]. The PG I / II ratio decreases with advancing extensive atrophic gastritis, since PG I is produced by chief and mucous neck cells in the fundus glands, which are impaired in case of gastritis of the fundus; while PG II is produced by the former cells and also by cardiac, pyloric and duodenal Brunner’s glands\[10\].

**DETECTION OF H. PYLORI IN OTHER SPECIMENS**

Other specimens have been evaluated to determine their usefulness to detect *H. pylori* infection. These include saliva\[12,13\], subgingival biofilm\[14\], dental plaque\[15\], gastric juice, gastroesophageal biopsy specimens\[16\] and adenontonsillar tissue\[17\]. Contradictory results have been reported regarding *H. pylori* detection in adenontonsillar tissue, either favoring\[18\] or against\[19\] adenontonsillar tissue as an extragastric reservoir of *H. pylori*. The ability to detect *H. pylori* antibodies in saliva is lower than in blood-based serology. However, the use of molecular techniques for the detection of *H. pylori* infection in saliva or dental plaque may make these specimens attractive because they are easier to collect\[18\]. The molecular techniques include PCR\[12,13,16\] and PCR-denaturing gradient gel electrophoresis (PCRDGGGE)\[18\]. Other techniques used to analyze these specimens are the RUT, immunohistochemistry and PNA-FISH\[18\].

The enterotest or string test was designed decades ago specially for children. The string test consists of a gelatin capsule attached to a 90-140 cm long nylon string that unwinds during ingestion. Upon reaching the stomach, the gelatin capsule dissolves and the string absorbs gastric secretions. The extraction of the string occurs 30-180 min later and should avoid contact with teeth and tongue to prevent contamination. The string may be used for culture (sensitivity 65% and specificity 99%) or PCR (sensitivity 79% and specificity 99%) for *H. pylori* detection\[18\].

**CONCLUSION**

Recent developments in both biopsy- and non-biopsy-based diagnostic methods for *H. pylori* infection will further contribute to improving current clinical approach and management of *H. pylori*-associated diseases.

We predict that in the future, standard and newer methods will evolve to improve the diagnostic yield of *H. pylori* infection detection in specific age groups (children versus adults) and clinical conditions, such as peptic ulcer bleeding, atrophic gastritis, post-gastrectomy status, as well as for wider application in epidemiological studies. The specific contribution of each method to the evolving strategies and algorithms for evaluation and management of *H. pylori* infection (test and treat) will remain of paramount relevance.

**REFERENCES**


Madan E, Midkiff BR. Egg yolk emulsion


Hatakeyama M. Anthropological and clinical implications for the structural diversity of the Helicobacter pylori CagA protein.


77 **Lin LL**, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach.* J Proteomics* 2012; 75: 3081-3097 [PMID: 22498866 DOI: 10.1016/j.jprot.2012.03.046]


P- Reviewers: Assem M, Kodama M, Pandya S, Ozcan C, Yucel O
S- Editor: Zhai HH
L- Editor: Stewart GJ
E- Editor: Zhang DN

Lopes AI et al. *H. pylori* diagnosis advances